vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Acushnet Holdings Corp. (GOLF). Click either name above to swap in a different company.
Acushnet Holdings Corp. is the larger business by last-quarter revenue ($477.2M vs $247.1M, roughly 1.9× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -7.3%, a 18.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 7.2%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-23.3M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -17.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
The Acushnet Company is an American company focused on the golf market. The company operates a series of brands that manufacture golf equipment, clothing and accessories.
ANIP vs GOLF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $477.2M |
| Net Profit | $27.5M | $-34.9M |
| Gross Margin | — | 44.1% |
| Operating Margin | 14.1% | -3.8% |
| Net Margin | 11.1% | -7.3% |
| Revenue YoY | 29.6% | 7.2% |
| Net Profit YoY | 367.5% | -3027.3% |
| EPS (diluted) | $1.14 | $-0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $477.2M | ||
| Q3 25 | $227.8M | $657.7M | ||
| Q2 25 | $211.4M | $720.5M | ||
| Q1 25 | $197.1M | $703.4M | ||
| Q4 24 | $190.6M | $445.2M | ||
| Q3 24 | $148.3M | $620.5M | ||
| Q2 24 | $138.0M | $683.9M | ||
| Q1 24 | $137.4M | $707.6M |
| Q4 25 | $27.5M | $-34.9M | ||
| Q3 25 | $26.6M | $48.5M | ||
| Q2 25 | $8.5M | $75.6M | ||
| Q1 25 | $15.7M | $99.4M | ||
| Q4 24 | $-10.3M | $-1.1M | ||
| Q3 24 | $-24.2M | $56.2M | ||
| Q2 24 | $-2.3M | $71.4M | ||
| Q1 24 | $18.2M | $87.8M |
| Q4 25 | — | 44.1% | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 49.2% | ||
| Q1 25 | — | 47.9% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 54.4% | ||
| Q2 24 | — | 54.4% | ||
| Q1 24 | — | 53.4% |
| Q4 25 | 14.1% | -3.8% | ||
| Q3 25 | 15.9% | 14.1% | ||
| Q2 25 | 6.6% | 15.2% | ||
| Q1 25 | 13.3% | 16.3% | ||
| Q4 24 | -2.3% | -1.2% | ||
| Q3 24 | -13.8% | 13.2% | ||
| Q2 24 | 3.7% | 15.5% | ||
| Q1 24 | 14.8% | 17.2% |
| Q4 25 | 11.1% | -7.3% | ||
| Q3 25 | 11.7% | 7.4% | ||
| Q2 25 | 4.0% | 10.5% | ||
| Q1 25 | 8.0% | 14.1% | ||
| Q4 24 | -5.4% | -0.3% | ||
| Q3 24 | -16.3% | 9.1% | ||
| Q2 24 | -1.7% | 10.4% | ||
| Q1 24 | 13.2% | 12.4% |
| Q4 25 | $1.14 | $-0.57 | ||
| Q3 25 | $1.13 | $0.81 | ||
| Q2 25 | $0.36 | $1.25 | ||
| Q1 25 | $0.69 | $1.62 | ||
| Q4 24 | $-0.45 | $0.02 | ||
| Q3 24 | $-1.27 | $0.89 | ||
| Q2 24 | $-0.14 | $1.11 | ||
| Q1 24 | $0.82 | $1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | $926.2M |
| Stockholders' EquityBook value | $540.7M | $783.6M |
| Total Assets | $1.4B | $2.3B |
| Debt / EquityLower = less leverage | — | 1.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | — | $926.2M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $753.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $783.6M | ||
| Q3 25 | $505.8M | $852.3M | ||
| Q2 25 | $436.8M | $808.5M | ||
| Q1 25 | $418.6M | $780.3M | ||
| Q4 24 | $403.7M | $765.2M | ||
| Q3 24 | $405.9M | $863.9M | ||
| Q2 24 | $455.8M | $863.7M | ||
| Q1 24 | $452.0M | $883.7M |
| Q4 25 | $1.4B | $2.3B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $2.4B | ||
| Q1 25 | $1.3B | $2.4B | ||
| Q4 24 | $1.3B | $2.2B | ||
| Q3 24 | $1.3B | $2.3B | ||
| Q2 24 | $920.8M | $2.3B | ||
| Q1 24 | $914.5M | $2.4B |
| Q4 25 | — | 1.18× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.98× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-338.0K |
| Free Cash FlowOCF − Capex | $29.1M | $-23.3M |
| FCF MarginFCF / Revenue | 11.8% | -4.9% |
| Capex IntensityCapex / Revenue | 0.5% | 4.8% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $120.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-338.0K | ||
| Q3 25 | $44.1M | $163.1M | ||
| Q2 25 | $75.8M | $151.9M | ||
| Q1 25 | $35.0M | $-120.3M | ||
| Q4 24 | $15.9M | $-1.1M | ||
| Q3 24 | $12.5M | $144.1M | ||
| Q2 24 | $17.4M | $211.6M | ||
| Q1 24 | $18.3M | $-109.5M |
| Q4 25 | $29.1M | $-23.3M | ||
| Q3 25 | $38.0M | $136.9M | ||
| Q2 25 | $71.8M | $138.0M | ||
| Q1 25 | $32.5M | $-131.5M | ||
| Q4 24 | $13.5M | $-33.2M | ||
| Q3 24 | $7.7M | $123.7M | ||
| Q2 24 | $13.0M | $196.8M | ||
| Q1 24 | $13.7M | $-116.8M |
| Q4 25 | 11.8% | -4.9% | ||
| Q3 25 | 16.7% | 20.8% | ||
| Q2 25 | 34.0% | 19.2% | ||
| Q1 25 | 16.5% | -18.7% | ||
| Q4 24 | 7.1% | -7.5% | ||
| Q3 24 | 5.2% | 19.9% | ||
| Q2 24 | 9.4% | 28.8% | ||
| Q1 24 | 10.0% | -16.5% |
| Q4 25 | 0.5% | 4.8% | ||
| Q3 25 | 2.7% | 4.0% | ||
| Q2 25 | 1.9% | 1.9% | ||
| Q1 25 | 1.3% | 1.6% | ||
| Q4 24 | 1.3% | 7.2% | ||
| Q3 24 | 3.2% | 3.3% | ||
| Q2 24 | 3.2% | 2.2% | ||
| Q1 24 | 3.3% | 1.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 3.36× | ||
| Q2 25 | 8.87× | 2.01× | ||
| Q1 25 | 2.23× | -1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.56× | ||
| Q2 24 | — | 2.96× | ||
| Q1 24 | 1.00× | -1.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
GOLF
| Titleist Golf Equipment | $293.8M | 62% |
| Footjoy Golf Wear | $102.0M | 21% |
| Other | $45.3M | 9% |
| Golf Gear | $36.1M | 8% |
